Pharmalink granted US patent for Busulipo

Stockholm, Sweden-based Pharmalink AB, a specialty drug company, says that the US Patent and Trademark Office has approved US Patent No 7,351,427, relating to the pharmaceutical composition, method of preparation and method of treatment by use of busulfan, which is the active agent in the company's Busulipo. The compound is a well-established chemotherapy agent used for myeloablation (severe suppression of bone marrow activity) as a preconditioning regimen to bone marrow stem cell transplantation, for example, in the treatment of leukemia. The patent application was filed in the USA in 2003 and will expire in 2020 (term a`djusted).

"This patent extends our robust product protection for Busulipo to the USA and we believe will considerably increase our chances of attracting partnerships aimed at speeding up the commercialization of Busulipo in key markets," commented Pharmalink's managing director, Johan Haggblad.

The reformulation underlying the Busulipo concept was conceived and developed by Moustapha Hassan and Zuzana Hassan at the Karolinska Institute in Sweden.